Jury Awards $130M In Wyeth Prempro Trial

Law360, New York (October 11, 2007, 12:00 AM EDT) -- Drug maker Wyeth Pharmaceuticals Inc. has lost a third trial over its controversial hormone replacement treatment, with a Nevada jury on Wednesday awarding $134.5 million to three women who blamed the drug for their breast cancer.

After a four-week trial and just two days deliberation the state court jury in Reno returned their verdict Wednesday afternoon, finding that Wyeth's menopause drugs Prempro and Premarin were defective and that the pharmaceutical giant was negligent in its marketing and selling of the products. Drug manufacturer Pfizer Inc. had...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.